Odonate Therapeutics LLC (ODT) Director Buys $23,300.00 in Stock
Odonate Therapeutics LLC (NASDAQ:ODT) Director Jeff L. Vacirca bought 1,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were acquired at an average cost of $23.30 per share, for a total transaction of $23,300.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Odonate Therapeutics LLC (NASDAQ:ODT) remained flat at $$23.00 during midday trading on Friday. 87,873 shares of the stock were exchanged, compared to its average volume of 330,383. Odonate Therapeutics LLC has a 1-year low of $22.31 and a 1-year high of $24.45.
Odonate Therapeutics Company Profile
Odonate Therapeutics, LLC is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC).
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.